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ABSTRACT: There has been a very limited number of high-
throughput screening campaigns carried out with Leishmania drug
targets. In part, this is due to the small number of suitable target
genes that have been shown by genetic or chemical methods to
be essential for the parasite. In this perspective, we discuss the
state of genetic target validation in the ﬁeld of Leishmania research
and review the 200 Leishmania genes and 36 Trypanosoma cruzi
genes for which gene deletion attempts have been made since the
ﬁrst published case in 1990. We deﬁne a quality score for the dif-
ferent genetic deletion techniques that can be used to identify
potential drug targets. We also discuss how the advances in genome-
scale gene disruption techniques have been used to assist target-
based and phenotypic-based drug development in other parasitic
protozoa and why Leishmania has lacked a similar approach so
far. The prospects for this scale of work are considered in the context of the application of CRISPR/Cas9 gene editing as a useful
tool in Leishmania.
KEYWORDS: Leishmania, gene knockouts, null, CRISPR/Cas9, target validation, pathogen, Trypanosoma cruzi, drug discovery
L eishmaniasis is a disease that mainly aﬀects those burdenedby extreme poverty, across large swaths of the tropics and
subtropics. It consists of a spectrum of human and animal dis-
eases caused by at least 20 species of parasites in the genus
Leishmania. The symptoms range from self-limiting ulcers to
the destruction of mucocutaneous surfaces to fatal disease caused
by visceral leishmaniasis; dermal sequelae can also occur following
the cure of primary visceral disease. There are up to 1.2 million
cases of cutaneous leishmaniasis and up to 0.4 million cases of
visceral leishmaniasis each year, resulting in up to 30 000 deaths.1
Collectively, 350 million people live at risk of catching leish-
maniasis due to the wide geographic range of the vector insects,
phlebotomine sand ﬂies. There are medicines available to treat
these diseases, but they have notable deﬁciencies due to emerging
resistance, poor safety proﬁles, and the long duration of treat-
ment, so more eﬀective treatments with improved safety and
dosing proﬁles are desirable. The complex picture of a spectrum
of diseases, in several organs, caused by diﬀerent parasite spe-
cies with diﬀering biology means that several new medicines
may be required to satisfy quite stringent target product proﬁles
(TPPs) for visceral and cutaneous leishmaniasis.2,3 New chem-
ical entities will probably require diﬀerent chemical features for
achieving the desired bioavailability in skin versus viscera cou-
pled with the challenge of drugging an intracellular parasite that
resides in a phagolysosomal compartment. There is growing
appreciation that Leishmania infections can also form quiescent,
persistent forms.4 Targeting these stages is desirable, though it
may also prove challenging. There are a number of ongoing drug
discovery programs that aim to address this need, typically
working within deﬁned phenotypic or target-based screening
strategies to best achieve success.2,3,5−8 Phenotypic or whole
organism screening selects for compounds that cause a loss of
parasite ﬁtness, whereas the target-based approach involves screen-
ing against a selected target of interest thought to be essential
to parasite survival. We will assess these approaches and the
role that genetic target validation can play within them.
■ TARGET VALIDATION IN DRUG DISCOVERY
PROGRAMS
Drug target validation for antiparasitic compounds consists of
acquiring the evidence that deﬁnes whether a target molecule
(usually a protein/enzyme) is selectively inhibited by a chem-
ical entity leading to the death of the parasite as well as the link-
age of the target molecule to an essential parasite process. The
evidence used to validate targets can arise from genetic
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manipulations of a pathogen or from the interrogation of the
organism with speciﬁc chemical probes. The strength of valida-
tion will depend on how much evidence is accrued, and well-
validated targets will be supported by both genetic and chem-
ical evidence.5,9 For noninfectious diseases, it is estimated that
selecting genetically supported targets doubles the success rate
in later stages of clinical development,10 highlighting the impor-
tance of genetic validation. The best validation of all comes when
the molecular target for a compound is known and the compound
is available on the market for clinical use, the one example for
trypanosomatids being the treatment of human African trypano-
somiasis with Eﬂornithine (diﬂuoromethylornithine, DFMO), a
compound that inhibits ornithine decarboxylase.11 It is notable
that for most antileishmanial drugs (miltefosine, paromomycin,
antimonials, and pentamidine) there are no target proteins iden-
tiﬁed despite extensive research, although amphotericin B is
reported to speciﬁcally target ergosterol-containing membranes.12,13
Phenotypic Screening. For Leishmania, several hit
compounds have been identiﬁed by phenotypic-based drug dis-
covery, which involves screening druglike molecules against
Leishmania axenic amastigotes or amastigotes in macrophages
to identify compounds that kill the parasites. This approach has
the advantage in that it can identify bioactive compounds that
have appropriate cell permeability characteristics to kill the par-
asite within the parasitophorous vacuole. One disadvantage is
that the screening is very stringent; consequently, few bioactive
compounds are identiﬁed.5 Another disadvantage is that one
does not immediately know the molecule being targeted by the
bioactive compounds. If a large (>1 million compounds) screen
is performed, then it may conceivably identify diverse target-
class inhibitors whereas sublibraries can be used to increase the
chances of hits within a certain target class, for example, by using
a protein kinase inhibitor-focused library.14 The optimization of
hit compounds by medicinal chemistry involves a level of ran-
domness in which it may not be immediately apparent which
functional groups of the molecule are the important pharmaco-
phores. Structural activity analyses are performed in whole cell
assays, and it is not possible to know if increases in activity against
parasites are concurrent with activity against a speciﬁc target.
Therefore, a campaign of target deconvolution is often initiated
to identify the molecular target of a hit compound. This can
involve a combination of forward genetic screens such as the
generation of resistant parasites and the identiﬁcation of mutant
alleles in the target gene by whole genome sequencing;15 aﬃn-
ity puriﬁcation of the target using a compound conjugated to
beads;16 and the use of overexpression libraries17,18 or metab-
olomics to identify blocks in biochemical pathways.19 It is also
important to have an understanding of an experimental com-
pound’s mode of action as this can enable an assessment of the
likelihood of resistance mechanisms evolving in the parasite.
Recent successful examples of the phenotypic screening of large
compound libraries or focused subset chemical libraries against
Leishmania parasites include the identiﬁcation of the “Leish-
Box” of inhibitors by GSK,20 the identiﬁcation of a selective
proteasome inhibitor (GNF6702) by Novartis,15 and the iden-
tiﬁcation of natural product inhibitors.21
Target-Based Drug Discovery. The alternative strategy of
target-based drug discovery is used extensively by the phar-
maceutical industry and has been applied to Leishmania; this
consists of the selection of a protein target and the develop-
ment of a biochemical or biophysical assay that can be used to
identify inhibitors of that target, followed by a high-throughput
screening (HTS) campaign. Hit compounds from such screens
are validated and then chemically optimized into lead compounds
that have improved properties in terms of potency, selectivity,
and bioavailability. This is a resource-intensive and costly pro-
cess and needs to be built on a solid understanding of why the
selected target is an appropriate choice, a process deﬁned as
target assessment. Drug targets are evaluated on the basis of gene
essentiality in addition to other criteria, for example, the presence
of close homologues in the parasite genome that may allow for
an easier evolution of resistance through functional redundancy.
Alternatively, single-point mutations in a gene may lead to drug
resistance with little associated cost to parasite ﬁtness. These
examples emphasize the importance of a good understanding of
parasite genetics for drug target prioritization. Other parameters
for target assessment include the potential druggability of the
protein, the availability of in vitro assays, the availability of struc-
tural information, and the presence of structurally similar proteins
in the host proteome that may present a potential risk for host
toxicity. The assessment of a target against each of these criteria
can be scored, generating a “traﬃc lights” rating: red ratings will
typically stop a target from progression, but those scoring green
should progress more easily through development.22 The level
of rigor in building a strong evidence base to support target-
focused approaches means that many targets are shown to be
invalid. For these reasons as well as due to the limitation of
ﬁnancial and material resources, there have been notably few
HTS campaigns against Leishmania proteins, namely, CRK3
(cyclin-dependent kinase),23 NMT (N-myristoyltransferase),24
and PTR1 (pteridine reductase).25 Casein kinase (LmCK1.2)
has also been the subject of an HTS campaign14 after being
chemically validated as a target.26,27
Drug Repurposing and Piggybacking. Alternatives
to developing or identifying new chemical entities to target
Leishmania exist in the form of drug repurposing, a strategy
where a compound that has been developed to treat one dis-
ease is used to treat another, diﬀerent disease. The beneﬁt of drug
repurposing is that the treatment can be used in patients relatively
quickly and with lower cost compared to de novo drug discovery.
Notable examples for leishmaniasis include the use of miltefosine,
amphotericin B, and pentamidine, which were all designed or
approved for other indications.6 Piggybacking is the concept of
identifying existing pharmaceutical material, investment, and knowl-
edge around a given target or inhibitor class and applying it to
infectious disease targets, but this usually stops short of direct
drug repurposing.
■ GENETIC TARGET VALIDATION IN LEISHMANIA
Leishmania has some biological features that have made it some-
what diﬃcult to genetically manipulate; it is highly prone to
aneuploidy, meaning that genetic modiﬁcation of essential genes
can be challenging or unstable.28−30 RNA interference does not
function in most Leishmania species.31 In those species where
RNAi does function, it has not been exploited to the same extent
as Trypanosoma brucei, primarily due to the lack of an inducible
system to investigate the function of essential genes. Leishmania
parasites are easily cultured and genetically manipulated as
promastigote stages, those found in the insect vector, but these
are not the relevant stage for human disease. It is therefore very
important to conﬁrm the essentiality of a potential target using
the amastigote stages of the parasite lifecycle. Some species of
Leishmania, such as L. mexicana, are readily converted to axenic
amastigotes in vitro32 and this can facilitate the study of gene
function in the pathogenic stages, but phenotypic analysis is
perhaps best carried out using macrophages to perform
ACS Infectious Diseases Perspective
DOI: 10.1021/acsinfecdis.7b00244
ACS Infect. Dis. XXXX, XXX, XXX−XXX
B
intracellular amastigote growth and survival assays and/or mouse
infections. Amastigotes can be genetically manipulated, but this
is not a common practice.33 Typically, an in vivo model is used
to demonstrate a ﬁtness or virulence defect of a genetically
engineered mutant.
Leishmania possess a very eﬃcient homologous recombina-
tion pathway for DNA repair that has been exploited as a basis
for generating gene deletions, integrating epitope tags, or expressing
transgenes.34 (See Table 1 for a deﬁnition of terms.) As the
technology to manipulate Leishmania has improved over time,
so has the ability to achieve more conﬁdence in a gene’s essen-
tiality. On the basis of the literature, we used a scoring system
for the strength of validation resulting from gene deletion stud-
ies, on a 1−5-star scale (Table 1 and Figure 1), and we discuss
these below, with examples. We propose that the higher scoring
methods provide better-quality evidence of a gene’s essentiality
but acknowledge that they are also associated with increased time
and eﬀort to generate the mutants. Despite this, we hope to use
this guide to inform good practices for Leishmania genetic
manipulation.
■ APPROACHES TO THE GENETIC MANIPULATION
OF LEISHMANIA
Deletion by Double Homologous Replacement and
Facilitated Null Mutants. In 1990, it was demonstrated that
genes could be deleted from Leishmania promastigotes by homol-
ogous replacement with linear dsDNA.35 The authors demon-
strated proof of concept, which involved deleting a single allele
of DHFR-TS in wild-type L. major. This was then repeated in a
strain that was already identiﬁed as heterozygous for DHFR-TS,
which permitted the deletion of the remaining allele using a
homology ﬂanked neomycin resistance cassette. The generation
of a DHFR-TS null mutant led to thymidine auxotrophy and could
only be achieved in the presence of thymidine nutritional sup-
plementation; removal of thymidine supplementation stalled
cell growth, demonstrating that DHFR-TS was essential for par-
asite survival. The complementation of the null mutant with an
episome expressing DHFR-TS restored wild-type growth levels,
indicating that the function of this gene could be reconstituted
genetically as well as chemically. This set the stage for
other researchers to begin performing reverse genetic analyses
in Leishmania. The development of new resistance markers
allowed for gene deletions of two alleles of a gene,36 given that
Leishmania was considered at the time to have a diploid genome
that allowed for the generation of null mutants from wild-type
backgrounds. In the following years, a number of papers dem-
onstrated that upon deletion of both alleles of a suspected essen-
tial gene the system would fail. Either no transfectants would
survive the drug selections, parasites would survive but had dupli-
cated their genome to retain the gene of interest as well as the
drug resistance markers,36 or there were extra copies of the gene
remaining on supernumerary chromosomes or ectopic elements
(Figure 1A). At the time, this was considered evidence for gene
essentiality, but with the inability to perform any further, this is
classiﬁed as the weakest form of evidence (one star) as the fail-
ure to generate a null mutant may result from a simple technical
failure. For example, as the technology for performing electro-
poration became more sophisticated, transfection eﬃciencies
increased, allowing some previously intractable genes to be revealed
as nonessential. The Metacaspase gene,MCA, initially could not be
deleted from L. major,37 and overexpression caused a growth
defect, which was interpreted to mean that the gene played an
essential role in cellular proliferation. However,MCA null mutants
could be generated in both L. major38 and L. mexicana39 using a
newer high-eﬃciency electroporation system that causes mini-
mal cellular damage. Generating this deletion allowed for the
characterization of the role of MCA in amastigotes and mice
where the null mutant exhibited an increase in virulence.39
Several studies have performed deletions that resulted in par-
asites auxotrophic for a given metabolite and required chem-
ical supplementation to allow null mutants to be recovered35,40
(Table S1). The advantage of a chemical complementation is that
it allows for rapid withdrawal and the resulting phenotype was
investigated. Where nutritional supplementation could not be used
to facilitate the deletion of essential genes, researchers began to
introduce an episomal copy of the gene of interest into the par-
asite prior to the deletion of the two chromosomal alleles41
(Figure 1B). This approach increases the conﬁdence in the val-
idation as it demonstrates that the failure to delete both alleles
of the gene of interest is not a technical failure or due to
Table 1. Deﬁnitions of Key Terms
term deﬁnition synonym
allele This is a variant form of a gene. For diploid chromosomes, there are two alleles in the nuclear
DNA (if identical, these are homozygous; if diﬀerent, these are heterozygous). Additional alleles
or copies of a gene can be complemented on an episome or integrated into the nuclear DNA in
wild-type, mutant, or ﬂoxed forms.
gene deletion by double
homologous replacement
An allele of a gene is replaced by a drug resistance marker, resulting in deletion of the coding
DNA sequence of the allele. This is performed twice, in sequential steps, with two diﬀerent drug
resistance markers to result in the replacement of two alleles of a gene, yielding a null mutant if
the gene is not essential.
knockout (verb)
null mutant This is a parasite strain that lacks both alleles of a gene of interest after a deletion strategy. knockout (noun)
facilitated null mutant Both chromosomal alleles can be deleted, but this requires prior genetic (episomal allele) or
nutritional supplementation.
episomal rescue, conditional
null mutant
unforced plasmid shuﬄe Drug selection for a plasmid episome that complements a chromosomal null mutant is removed,
and the loss or retention of this plasmid is analyzed.
plasmid cure
forced plasmid shuﬄe The complementing plasmid episome contains both a positive and negative selectable marker,
which allows a selection pressure to be imposed to favor parasites that lose the episome.
inducible gene deletion A parasite line is engineered to contain an allele that can be removed by the addition of a trigger,
for example, the rapamycin-induced DiCre recombinase deletion of a ﬂoxed allele.
ﬂoxed Flanked by the loxP (locus of X-overP1) site, this term is used to describe alleles of genes that can
be inducibly deleted by a Cre or DiCre (inducible dimerizable Cre) recombinase system.
complementation This involves the restoration of null mutants by the addition of an extra allele of the gene of
interest (episomally or genomically) or by the addition of a nutritional supplement in the case
of a gene that encodes a metabolic enzyme.
add back
episome A circular DNA molecule that can be replicated independently of the nuclear or kinetoplast DNA. plasmid
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the locus being refractory to genetic manipulation (Figure 2B,
two stars).
An episome expressing a gene in a null mutant background
will be retained if it confers a selective advantage for growth,
Figure 1. Overview of techniques that can be used for genetic target validation in Leishmania. (a) Gene deletion by homologous replacement. Drug
resistance markers are targeted to the gene of interest by long homology ﬂanks (0.5−1 kb) in sequential transfections by electroporation. This
process can now be facilitated using CRISPR/Cas9 and short homology ﬂanked cassettes in a single transfection. Deletions targeting essential genes
will result in cell death and failure to isolate null mutants or in ploidy changes that allow the cell to retain alleles of the wild-type locus as well as drug
resistance markers. (b) Facilitated null mutant with unforced plasmid shuﬄe. An episome expressing the gene of interest is ﬁrst transfected into the
cell line or a nutritional supplement is provided, allowing it to survive the subsequent deletion of the chromosomal alleles of the gene of interest. The
drug selection pressure for the episome can be removed and retention of the plasmid can be determined if the gene is not essential; then it will be
possible to isolate parasites that lack the episome. (c) Forced plasmid shuﬄe. As in B, an episome expressing the gene of interest is transfected into
the parasite to allow the deletion of the chromosomal alleles of the target gene. The episome also encodes a negative-selectable marker, herpes
simplex virus thymidine kinase. Selection with ganciclovir favors the survival of parasites that lack the episome, so if a gene is nonessential, the
episome will rapidly be lost from the population but will be retained for an essential gene despite the associated costs. The addition of a second
episome containing mutant versions of the gene of interest allows for exploration of the roles of speciﬁc domains and residues in the encoded protein
for correct gene function by assessing which plasmid of the two is preferentially retained. (d) DiCre inducible gene deletion. One allele of the target
gene is replaced by a drug-selectable cassette containing a “ﬂoxed” allele, and in a second transfection stage, the remaining allele is replaced by a
second drug resistance marker. The addition of rapamycin induces DiCre dimerization and excision of the ﬂoxed allele, and the phenotypes that
emerge in the induced null mutants can then be analyzed. As in C, complementation allows for the assessment of null mutant speciﬁcity and
functional assessment of deﬁned domains or residues in the protein. In all panels, the number of stars indicate the quality of the genetic evidence for
gene essentiality, with one star being the weakest and ﬁve stars being the strongest.
ACS Infectious Diseases Perspective
DOI: 10.1021/acsinfecdis.7b00244
ACS Infect. Dis. XXXX, XXX, XXX−XXX
D
even if the gene is dispensable for parasite viability. In a
facilitated null mutant of a nonessential gene, the episome can
be lost in the absence of drug selection, and a null mutant is
generated. For essential genes, even after prolonged culturing of
the facilitated null mutant in a medium that lacks drug selection
for the episome or by passaging the parasites through mice, the
episome will be retained. This is considered indirect evidence
that the gene is essential (Figure 1B, three stars). However, most
episomes cannot be forced from the parasite, so this still does
not provide direct evidence for gene essentiality or allow the
phenotype analysis of loss-of-function mutants.
Facilitated Null with Negative Selection/Forced
Plasmid Shuﬄe. As an improvement in the ability to select
for the loss of the episome in a facilitated null mutant, negative
selection or forced plasmid shuﬄe can be achieved using neg-
ative selectable marker herpes simplex thymidine kinase (TK). Gan-
ciclovir is used to impose a ﬁtness cost on parasites that retain
the plasmid, selecting for parasites that lose the episome. If it is
complementing an essential gene, then the parasites must retain
the plasmid to remain viable, so any loss will prove fatal. The
inclusion of a green ﬂuorescent protein (GFP) reporter gene
helps to distinguish cells containing the episome, which is useful
for ﬂuorescence-activated cell sorting (FACS) of diﬀerent pop-
ulations of cells (Figure 1C).
This strategy was ﬁrst applied to Leishmania major to inves-
tigate the role of 5,10-methylene tetrahydrofolate dehydrogen-
ase (DHCH) in 10-formyl tetrahydrofolate (10-CHO-THF)
metabolism42 following the failure of classic gene deletion and
nutritional supplementation strategies. DHCH1 was expressed
from an episome (also containing TK and GFP), allowing a facil-
itated null mutant to be generated. The episome was selected
against using ganciclovir, and parasites were then ﬂow sorted
into GFP bright or dim populations and cloned into 96-well
plates. The dim clones, lacking the DHCH1 episome, were not
viable and failed to grow. This system has also been used to
examine the essentiality of MAP kinase 4 (MPK4) in L. major
promastigotes in a manner allowing more detailed functional
genetic analysis.43 A facilitated null mutant was achieved by epi-
somal complementation, followed by forced plasmid shuﬄe to
assess gene essentiality. After ascertaining that MPK4 was essen-
tial for promastigote viability, the authors complemented with a
panel of secondary episomes (lacking TK) containing functionally
mutated versions of MPK4. This allowed for exploration of the
Table 2. Scoring System to Assess the Quality of Evidence for Target Essentiality by Gene Deletion Techniques
Leishmania Trypanosoma cruzi
quality score deﬁnition issues number genes number genes
* failure of attempt to perform
gene deletion by double
homologous replacement
changes in ploidy
indicative of
essentiality; may be a
technical failure
30 TR, A2-A2REL, SODB1, LACK, PK,
CRN12, TOR1, TOR2, SPASE I,
MYO21, HSLU1, LHR1, HUS1,
HEMAC, ENDOG, ASNA, ARP,
RAD51-6, AIRK, LMIT1, RAD50,
TYRRS, ABC3, RAB5A, RAB5B, TWF,
SIR2RP2, SODA, ACECS, CPN10
15 TC52, DHOD,
GALE, DHFR-TS,
ECH1, SUB2,
GPI8, GPI12,
CRT, IP3R, RPA2,
GALF, CYP51,
STI1
** facilitated null mutant; gene
of interest is complemented
with an episome or
nutritional supplement,
allowing genomic alleles to
be deleted
shows the gene locus can
be targeted for deletion
20 TUB, CRK1, NMT, SIR2, RPC2, TOPS,
TXN1, GSH1, GLO1, SGT, DHS34,
HSLV, NTR, TRYS, CYP51EIF4E,
RAD51-3, RPIB, RAD9, LYSRS-1
1 NMT
*** unforced plasmid shuﬄe;
plasmid retained in the
absence of antibiotic
selection
indirect evidence for a
gene being essential;
best carried out in vivo
12 PRT1, ODC, DHFR-TS, SPSDS,
ADOMETDC, ARG, DHCH1, STI1,
UMPS, CPS, UPRT
**** forced plasmid shuﬄe or
DiCre inducible deletion
death of parasite after
induction used as
evidence of essentiality
2 H2A.Z, H2B.V, MPK4
***** as above but with analysis in
amastigote stages and/or
the mouse model
application to
amastigotes provides
best evidence for
essentiality in vivo
1 CRK3
Figure 2. Overview of the number of Leishmania genes with published
attempts at the creation of a null mutant. (a) Line graph depicting the
cumulative number of genes for which attempts have been made to
generate null mutants, for human infective Leishmania species. Only
the ﬁrst attempt at a gene deletion for each individual gene was
recorded. Data from this study were ordered by year, and cumulative
values of publications per year were derived, where the total number of
attempted gene deletions is shown as well as the number of essential
genes identiﬁed. (b) Pie chart showing the proportion of unique gene
deletion attempts by species of Leishmania. Cutaneous species are
shaded in yellows, and visceral species, in blues.
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importance of protein motifs and residues for MPK4 ATP bind-
ing, activity, and activation by upstream MKKs. This study
highlighted the power of plasmid shuﬄe in that an MPK4 mutant
with altered ATP binding properties, predicted to have reduced
protein kinase activity, could replace wild-type MPK4, resulting
in resistance to acidic stress. The results from this study support
previous facilitated null and unforced plasmid shuﬄe data sug-
gesting that MPK4 from L. mexicana44 is essential to the mam-
malian infection cycle. Proﬁling of null mutant phenotypes in
the amastigote stage is critical to the validation of drug targets,
so the compatibility of the plasmid shuﬄe with this is welcome.
However, a limitation of the plasmid shuﬄe approach is that null
mutants of essential genes are never generated in the absence of
ganciclovir (which acts as a cytostatic but not a cytocidal drug),
so direct analysis of the null mutant phenotypes is not possible.
In reference to the suitability of MPK4 as a drug target, it has so
far been impossible to identify a biochemical assay for the screen-
ing of small-molecule inhibitors, mainly due to its lack of pro-
tein kinase activity against generic substrates.43 Currently, this
lack of an enzymatic activity assay renders MPK4 a genetically
well-validated but poorly tractable target for drug discovery
programs.
DiCre Inducible Deletion. In order to directly measure the
loss of gene function, a population of cells would ideally be sub-
jected to an inducible gene deletion approach, allowing synchro-
nous, direct analysis of emerging phenotypes in real time. A tech-
nique that has recently been applied to Leishmania to directly
study gene function is the DiCre inducible gene deletion strat-
egy45 (Figure 1D). This was ﬁrst used in Leishmania mexicana
to inducibly delete the cyclin-dependent protein kinase, CRK3,
a gene that had previous indirect evidence for essentiality in
Leishmania.46 Prior to the study by Duncan et al., there was a
signiﬁcant body of indirect genetic evidence for CRK3 essen-
tiality, such as changes in ploidy associated with attempts to
delete both alleles and that it was possible to delete both chro-
mosomal alleles only in the presence of an episome expressing
CRK3, with the episome being retained in the absence of drug
selection.46 Other chemical evidence existed for CRK3 to be a
potential drug target as known inhibitors of CDKs were shown
to induce a G2/M cell cycle block and halt parasite
growth.46−48
This DiCre-mediated deletion of CRK3 involved replacing a
genomic allele of the gene with a version ﬂanked by loxP sites
(ﬂoxed), the second copy replaced by a cassette encoding two
subunits of the Cre recombinase, fused to rapamycin binding
domains45 (Figure 1D). Once this strain was generated, the dimer-
ization of Cre subunits was initiated by the addition of rapamycin,
forming a functional Cre recombinase that excised the remain-
ing ﬂoxed copy of the gene of interest, resulting in a null mutant
(Figure 1D). The advantage of this system is that phenotypes
emerging from the gene deletion can be studied over several
days, and the mechanism of cell death or dysregulation can be
elucidated. The disadvantage is that RNA and protein remain in
the cell after DiCre-induced deletion of the gene and the pheno-
type may take several rounds of cell division before becoming
apparent.
By performing the DiCre analysis, Duncan et al. were able to
delete the CRK3f lx gene from promastigote cells and observe
precisely the phenotype resulting in CRK3 null mutant−cell
cycle (G2/M) arrest, the initiation of G1 phase in the absence
of cytokinesis, and impaired cytokinesis leading to an increase
in both multinucleated cells and “zoids” (cells lacking nuclear
DNA content) and associated cell death. Cell lines were
complemented with both wild-type CRK3 and CRK3T178E
(a mutation in the activation loop) genes to demonstrate that
the phenotype was speciﬁc to CRK3 deletion, that the presence
of threonine 178 in the activation loop of the protein kinase
domain was important for proper function, and that CRK3T178E
could not complement the loss of wild-type CRK3. Not only
did this study show the importance of CRK3 in promastigote
stages, but the gene was deleted in stationary phase cultures
(metacyclic-enriched), allowing the parasites to be inoculated into
mice and the progress of the infection to be monitored by
noninvasive, bioluminescent imaging using a strain engineered
to express red-shifted luciferase. CRK3 was shown to be important
for the establishment and maintenance of infection by a reduction
in bioluminescence from mice infected with the CRK3-deﬁcient
cells. This was ranked as a ﬁve-star validation (1, Figure 1D).
Despite the now extremely good genetic validation of L. mexicana
CRK3 as an essential gene, a previous HTS campaign (against
LmxCRK3/CYC6) failed to identify compounds that had bio-
activity against the parasite in macrophages.49 The compounds
identiﬁed failed to inhibit parasite growth in macrophages despite
having good physiochemical properties and having diﬀerent scaf-
folds, suggesting that these compounds failed because of some
unknown aspect of CRK3 biology in Leishmania or unknown bio-
availability within the parasitophorous vacuole, thus CRK3/CYC6
has not been fully chemically validated.
A more deﬁnitive assessment of essentiality would be to induce
gene deletions in amastigotes during animal infections. This
experiment is not possible with the DiCre system due to the
lack of bioavailability of rapamycin/rapalogues and the toxicity
of rapamycin to amastigotes. Such a model would enable research-
ers to observe that an experimental infection was not compro-
mised during the establishment phase, but upon inducible dele-
tion of an essential gene the infection would fail and be resolved
by the host immune system.
■ OVERVIEW OF EXISTING GENE DELETION
ATTEMPTS
To assess the current state of target validation in Leishmania, a
literature search was performed to identify all instances where
these genetic techniques have been used to attempt to generate
null mutants in human pathogenic Leishmania (Figure 2A,
Table S1). We focused on identifying the ﬁrst instance where
researchers had attempted to generate a null mutant for a given
gene, but we do not provide a comprehensive review of every
genetic study on the same gene in multiple species of Leishmania.
The strategy used to attempt the genetic deletion was identiﬁed,
whether this was successful or not, along with a broad catego-
rization of the phenotype, i.e. essential for promastigotes, con-
ditionally essential, or nonessential. If a complementation was
required, it was deﬁned if this was genetic or a nutritional sup-
plementation. Two hundred genes were identiﬁed, where attempts
have been made to make null mutants in promastigotes of var-
ious Leishmania species; 65 were classiﬁed as essential, and the
remaining 135 were classiﬁed as nonessential. The rate of genetic
deletion studies being published appeared to accelerate after 2008,
possibly due to the publication of the L. major genome in 200550
and the L. braziliensis and L. infantum genomes in 2007,51 but
has remained fairly constant between 2008 and 2017. Our liter-
ature search identiﬁed a range of diﬀerent species of Leishmania
under investigation, including those responsible for both cuta-
neous and visceral diseases (60 vs 40%, respectively), with
L. major (37%) being the most commonly studied, followed by
L. donovani (29%) (Figure 2B).
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A gene ontology (GO) analysis was performed on the 200
genes using TriTrypDB52 and REVIGO53 (Figure 3, Table S1).
GO was analyzed by clustering to describe the biological pro-
cesses that are performed by the 200 gene products. Clear clus-
ters emerge for processes involved in nutrient transport and
stress response, and broader clusters emerge for metabolic pro-
cesses including nucleotide salvage and synthesis. There are many
instances of GO terms associated with oxidation−reduction
processes and protein modiﬁcation such as protein folding, pro-
teolysis, and protein phosphorylation, demonstrating the strength
of research on metabolism, peptidases, and protein kinases. Impor-
tant single gene processes were also identiﬁed, such as N-terminal
protein myristoylation.
Because of the high variability in the assay protocols used for
phenotypic analyses in each study, it is challenging to allocate
each gene deletion mutant to a deﬁned phenotypic category, other
than essential or nonessential to promastigotes. For example,
gene deletions that confer altered virulence may be essential
in a given context such as mammalian infection, but the
classiﬁcation of these phenotypes can be quite subtle or depen-
dent on the species, infectious dose, or mouse strain used and is
outside the scope of this Perspective. In this regard, there is a clear
need for a comparative analysis of Leishmania null mutants, where
the same genetic approaches and phenotype analysis can be car-
ried out on a large scale, which is discussed in the next section.
By way of comparison and to extend the analysis, the literature
was also reviewed to identify Trypanosoma cruzi genes for which
the creation of null mutants had been attempted (Table S2).
The genetic tools available for Leishmania are broadly appli-
cable to Trypanosoma cruzi in that this organism also has a func-
tional homologous recombination system and can support the
expression of genes from episomes.54,55 As for Leishmania, we
focused on identifying the ﬁrst study to report the deletion
attempt for any given gene. On the basis of our ﬁve star scoring
system, studies on T. cruzi did not reach a high-quality level of
drug target validation. Since 1993, only 36 genes had deletion
attempts reported in the literature, and 16 were considered to
be essential in epimastigotes (Figure 4, Table S2). Only one
Figure 3. REVIGO analysis of GO terms associated with targeted Leishmania genes. L. major orthologues for all gene IDs in Table S1 were used to
recover the associated GO terms for biological processes. The number of occurrences of each GO term was used to weight a REVIGO analysis,
depicted as larger circles and hotter colors. The more frequently occurring biological processes are annotated in the ﬁgure, as are key (but less
frequent) GO terms such as N-terminal protein myristoylation.
Figure 4. Number of reverse genetic manipulations of Leishmania in comparison to other model parasitic protozoans. (A) Comparison of reverse
genetic screening in Leishmania spp. (Table S1), Trypanosoma cruzi (Table S2), Trypanosoma brucei,59 Toxoplasma gondii,60 and Plasmodium
berghei.67 Pie chart segments depict the proportion of genes in each organism that have been targeted using reverse genetics, with the overall area of
the pie depicting the relative sizes of the genomes.
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study, of NMT,56 used a variant of the facilitated null approach
to validate the target gene; the deletion of both chromosomal
alleles was not possible until a “rescue” allele was integrated
into the ribosomal locus of the parasite. This demonstrated that
the generation of chromosomal allelic deletions was possible,
but only after genetic complementation; therefore, the gene is
likely to be essential. However, because the rescue allele was
integrated into the genomic DNA there was no possibility to
test that it could be lost to create a true facilitated null cell line.
Recently, DiCre57 systems were applied to T. cruzi, opening the
possibility for better target validation.
■ PROSPECTS FOR LARGE-SCALE GENETIC
MANIPULATIONS OF LEISHMANIA: LESSONS
FROM OTHER PROTOZOA
When compared to other, more genetically tractable protozoan
parasites, the situation in Leishmania looks limited, mainly due
to the low throughput of the prevailing techniques used to gen-
erate Leishmania gene deletions. Through a brief description of
tools and screens that have been used in other kinetoplastids
and apicomplexans, despite the unique biology and technical
challenges each organism and method present, desirable fea-
tures for future genetic screens in Leishmania can be identiﬁed.
To date, the genetic manipulation of Leishmania has been on a
gene-by-gene basis, yet several other parasitic protozoa such as
Trypanosoma brucei and Toxoplasma gondii have been amenable
to genome-wide screens58−60 (Figure 4). Combining these
massively paralleled genetic depletion resources with various
selection pressures can yield sophisticated experiments that are
able to interrogate, identify, and validate drug targets and elu-
cidate resistance mechanisms.
Most relevant to Leishmania target validation is the use of RNAi
screening in T. brucei, which evolved from gene-by-gene projects to
genome-wide RNAi screens58,59 and medium-throughput gene
family screens.61,62 These massively paralleled RIT-seq (RNA
interference target sequencing) experiments have led to the
identiﬁcation of genes essential for life cycle progression, drug
resistance, and the response to stress.63,64 Of particular rele-
vance is the way that this technology was used to identify
organelles, proteins, and metabolic pathways responsible for the
mode of action of trypanocidal drugs65,66 as this may be used to
shed light on pan-kinetoplastid biology and drug targets.
Other model pathogens such as Plasmodium berghei have also
been subject to high-throughput gene deletion screens. Although
less amenable to genetic manipulation, a herculean eﬀort has
allowed half of the P. berhei genome to be assessed for essen-
tiality67,68 (Figure 4). The PlasmoGem project used recombin-
eering to build libraries of long-homology ﬂanked deletion
vectors that can be transfected into parasites prior to infecting
mice.67,68 Pooling these libraries allowed for more than half of
the parasite’s genes to be assessed for their role in parasite
ﬁtness by sequencing DNA barcodes that were included in the
null mutants. This analysis suggested a wealth of drug targets as
∼60% of the P. berghei genes were considered essential. This
compares to ∼30% in T. brucei, and on the basis of our liter-
ature search, we expect Leishmania to be similar to 32.6% of the
Leishmania genes investigated so far that are essential.
Increased throughput and eﬃciency for the genetic manip-
ulation of parasitic protozoa has occurred by the adoption of
CRISPR/Cas9-mediated gene disruption and editing, with the
ﬁrst genome-wide screen in a parasite performed in Toxoplasma
gondii.60 T. gondii has a propensity for repairing double-stranded
DNA breaks by error-prone, nonhomologous end joining
(NHEJ), allowing for the inactivation of genes by frame-shifting
insertions or deletions. Next-generation sequencing was used to
quantify the remaining sgRNAs in the population and thus cal-
culate a score for how important a given gene is for parasite ﬁt-
ness. When combined with the comparative genomic assess-
ment of essential T. gondii genes to conserved genes in other
apicomplexans, the authors identiﬁed potential pan-apicomplexan
targets, some of which were then investigated and conﬁrmed as
essential in Plasmodium falciparum. The recent application of
CRISPR/Cas9 to Leishmania may enable such genome-wide
screening, but this requires further development.69−73 This is
due to Leishmania lacking a functional NHEJ pathway, although
it can repair a double-strand break using microhomology-mediated
end joining (MMEJ). Despite this, the medium-throughput
analysis of gene families in Leishmania is now a reality using the
highly eﬃcient L. mexicana T7/Cas9 system. This method uses
PCR amplicons for both sgRNA and repair templates with no
cloning steps, both alleles can be targeted in a single trans-
fection, and drug selection in pools has a high eﬃciency.73 These
factors permit easy and fast deprioritization of nonessential genes
from a family of potential targets.
Combined with the ability to generate facilitated null mutants,
CRISPR/Cas9 approaches can begin to provide indirect evi-
dence for a gene’s essentiality. Indeed, we expect that soon the
number of CRISPR/Cas9 genetic deletion attempts in Leishmania
will rapidly exceed the total number of gene deletions generated
between 1990 and 2017, possibly even genome-wide. Because
the other genetic techniques, such as DiCre, are more labor-
intensive, it would be beneﬁcial to focus them on prioritized
genes that cannot be deleted by CRISPR/Cas9; therefore,
CRISPR/Cas9 should facilitate faster and more detailed studies
on genes that have interesting or essential functions. CRISPR/Cas9
systems have also been developed for T. cruzi, further
expanding the toolbox for genetic manipulation.72,74,75
While constructing the spreadsheet of attempted gene dele-
tions, we were struck by the range of diﬀerent phenotypic ana-
lyses that were performed, which restricted placing genes into
neat categories based on the type or strength of phenotype
observed. One of the beneﬁts of cell library screens or massively
paralleled approaches is the ability to simultaneously analyze all
of the mutants in the same assay, which allows for an easier com-
parison of phenotypes. The integration of such data into EuPathDB
would make an exceptionally useful resource.52 Target selection
for Leishmania can be guided by mining the data sets available
in resources such as TriTrypDB, so we encourage fellow
researchers to contribute to this community resource with both
historical and current data.
■ CONCLUSIONS
The discovery of new drugs for intracellular pathogens is a com-
plex process that usually has a low chance of success. In order
to give it the best chance, the evidence needed to support the
process must be of a high standard. The optimization of existing
genetic techniques, the development of new techniques, and
the application of best practices is critical for identifying and
validating novel druggable targets. A balanced approach between
target-based drug development and phenotypic screening, sup-
ported by genetic tools for molecular target validation, is desir-
able. High-quality genetic tools now available for conducting
research on potential drug targets in Leishmania are optimal,
and the new technologies available will facilitate and improve
the number of genetically well-validated targets suitable for
entry into HTS campaigns.
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